Loading
The first randomised trial of AI in breast screening found more cancers and cut radiologists' reading work almost in half without more false alarms.
The prespecified interim safety analysis (Lancet Oncology 2023) of 80,020 women reported a cancer detection rate of 6.1 per 1,000 in the AI-supported arm versus 5.1 per 1,000 with standard double reading, similar recall rates (2.2% versus 2.0%) and false-positive rates (1.5% in both), and a 44.3% reduction in screen-reading workload. The final analysis of the full cohort (published 2025) confirmed a 29% increase in cancer detection, driven by small invasive cancers and in situ disease, with the interval-cancer endpoint to follow. MASAI is the evidence base for the AI-as-one-reader model that several European programmes, and the NHS EDITH trial, are now adopting.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC).
Shares Screening, Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC).
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Screening, Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.